Palatin Unveils Dual-Action Glaucoma Therapy PL9588 with Promising Preclinical Outcomes Palatin Technologies has introduced encouraging preclinical findings for its melanocortin agonist PL9588, aiming to transform glaucoma treatment with dual benefits.

Palatin Unveils Dual-Action Glaucoma Therapy PL9588 with Promising Preclinical Outcomes #United_States #Palatin_Technologies #Cranbury #Glaucoma_Treatment #PL9588